Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 129 results:
[ Συντάκτης] Τίτλος Τύπος Έτος Φίλτρα: Συντάκτης is Polyzos, Stergios A [Clear All Filters]
Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis..
Metabolism. 60(3), 313-26.
(2011). Off-label uses of denosumab in metabolic bone diseases..
Bone. 129, 115048.
(2019). Adipocytokines in insulin resistance and non-alcoholic fatty liver disease: the two sides of the same coin..
Med Hypotheses. 74(6), 1089-90.
(2010). Adipokines in nonalcoholic fatty liver disease..
Metabolism. 65(8), 1062-79.
(2016). infection and esophageal adenocarcinoma: a review and a personal view..
Ann Gastroenterol. 31(1), 8-13.
(2018). Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name..
Metabolism. 113, 154413.
(2020). Helicobacter pylori and insulin resistance association: not just a myth, not yet a fact..
Saudi J Gastroenterol. 17(6), 425-6.
(2011). Adipose tissue, obesity and non-alcoholic fatty liver disease..
Minerva Endocrinol. 42(2), 92-108.
(2017). Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics..
Metabolism. 92, 82-97.
(2019).
(2022). Helicobacter pylori infection in patients with nonalcoholic fatty liver disease..
Metabolism. 62(1), 121-6.
(2013). Nonalcoholic fatty liver disease test: an external validation cohort..
Hormones (Athens).
(2023). Denosumab treatment for juvenile Paget's disease: results from two adult patients with osteoprotegerin deficiency ("Balkan" mutation in the TNFRSF11B gene)..
J Clin Endocrinol Metab. 99(3), 703-7.
(2014). Mild leukopenia following denosumab treatment in a woman with postmenopausal osteoporosis..
Endocrine. 62(2), 487-489.
(2018). Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid..
Support Care Cancer. 17(10), 1329-30.
(2009). Irisin: A true, circulating hormone..
Metabolism. 64(12), 1611-8.
(2015). Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index..
Ann Hepatol. 12(5), 749-57.
(2013). Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)..
Metabolism. 154318.
(2020). The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature..
J Clin Gastroenterol. 45(1), 50-4.
(2011). Activin A and follistatin in patients with nonalcoholic fatty liver disease..
Metabolism. 65(10), 1550-8.
(2016). Helicobacter pylori Infection: One More Contributor to Nonalcoholic Fatty Liver Disease Pathophysiology..
J Clin Gastroenterol.
(2019). Helicobacter pylori infection and diabetes mellitus..
Diabetes Metab Syndr. 15(3), 845-846.
(2021). Serum homocysteine levels in patients with nonalcoholic fatty liver disease..
Ann Hepatol. 11(1), 68-76.
(2012). Irisin: a renaissance in metabolism?.
Metabolism. 62(8), 1037-44.
(2013).
(2018).